Opinion|Videos|August 21, 2024
Coexisting Cardiometabolic Conditions and Hypercortisolism
Medical experts discuss the implications of finding hypercortisolism in one-third of patients on three or more hypertension medications, the linkage between hypercortisolism and type 2 diabetes as presented in the ‘Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes’ session, and how hypercortisolism affects diabetes management, including the importance of addressing it and its consequences for patients with difficult-to-control diabetes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
How do you interpret the finding that one-third of patients on three or more hypertension medications also had hypercortisolism?
- You presented the ‘Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes’ at the last ADA scientific session. Can you briefly explain the linkage between hypercortisolism and diabetes?
- How does hypercortisolism physiologically impact the management of T2D?
- Why is it important to address hypercortisolism? What are the consequences of untreated hypercortisolism in patients with diabetes?
- What are the clinical implications of this data? How does it inform or change the way we manage patients with difficult-to-control diabetes?
Advertisement
Related to this article
In a phase 2 decentralized study, once-daily trientine tetrahydrochloride improved convenience and adherence in Wilson disease; 80% preferred it.
Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.
In adults with late-onset PFIC, odevixibat improved pruritus within 3 months in a real-world study at presented at The Liver Meeting 2026.
CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.
In patients with compensated MASH cirrhosis, Baveno VII and ANTICIPATE-NASH showed moderate agreement with HVPG and underestimated CSPH prevalence.
Robert Mentz, MD, discusses mentorship, trial recruitment, journal growth, and surgical partnerships in heart failure care.
At GOLD 2026, Alvar Agustí, MD, PhD, speaks on COPD underdiagnosis and misdiagnosis, barriers to spirometry in primary care, and managing pre-COPD.
In the phase 2b VISTAS trial, volixibat improved sleep vs placebo in PSC with cholestatic pruritus, and itch responders saw greater fatigue and sleep gains.
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
Conference Preview: 2026 GOLD International COPD Conference
3
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
4
Oral STAT6 Degrader KT-621 Reduces EASI by 62.6% in Atopic Dermatitis
5